Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PLSE |
---|---|---|
09:32 ET | 1122 | 17.11 |
09:36 ET | 3400 | 17.28 |
09:38 ET | 3035 | 17.21 |
09:39 ET | 103 | 17.04 |
09:41 ET | 100 | 17.04 |
09:43 ET | 600 | 17.5 |
09:45 ET | 1000 | 17.4944 |
09:50 ET | 300 | 17.5 |
09:52 ET | 100 | 17.4651 |
09:56 ET | 100 | 17.315 |
09:57 ET | 1000 | 17.32 |
10:08 ET | 400 | 17.25 |
10:12 ET | 100 | 17.26 |
10:14 ET | 766 | 17.16 |
10:15 ET | 100 | 17.1 |
10:19 ET | 397 | 17.04 |
10:24 ET | 723 | 17.02 |
10:35 ET | 300 | 17.005 |
10:37 ET | 240 | 17.1481 |
10:44 ET | 700 | 17.18 |
10:51 ET | 280 | 16.87 |
10:57 ET | 2100 | 16.9 |
11:00 ET | 2400 | 16.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Pulse Biosciences Inc | 1.1B | -21.4x | --- |
Atlantic International Corp | 322.6M | -0.7x | --- |
Nano-X Imaging Ltd | 359.2M | -6.1x | --- |
Simulations Plus Inc | 627.0M | 65.6x | +3.18% |
IRadimed Corp | 616.5M | 33.7x | +21.02% |
Clearpoint Neuro Inc | 314.6M | -15.9x | --- |
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.74 |
EPS | $-0.79 |
Book Value | $0.80 |
P/E Ratio | -21.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.